Schedule 13G ownership disclosure

AN2 Therapeutics, Inc.

Common Stock, par value $0.00001 per share · CUSIP: 037326105

Event date: 2026-03-09

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Commodore Capital LP

    Shares: 3,697,435.00 · Class: 9.9%

  • Commodore Capital Master LP

    Shares: 3,697,435.00 · Class: 9.9%

  • Robert Egen Atkinson

    Shares: 3,697,435.00 · Class: 9.9%

  • Michael Kramarz

    Shares: 3,697,435.00 · Class: 9.9%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001831942-26-000014
Form type
SCHEDULE 13G
Filer
AN2 Therapeutics, Inc.
CIK
CIK 1880438
Filed
Mar 16, 2026
Reporting period
Mar 09, 2026
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub